Berkley E. Gryder

The paper identifies a core regulatory circuit in rhabdomyosarcoma and shows that targeting two co-activators synergistically inhibits tumor growth.

The paper introduces compPASS, a tool to identify Pol2 failure modes in cancer, revealing rare modes linked to gene regulation and therapy response.

This study integrates single-cell and spatial transcriptomic data across species to identify conserved and distinct tumor ecosystems in osteosarcoma, revealing canine models as more faithful and highlighting ECM signaling in metastatic lesions.

The paper identifies two classes of Pol2-mediated chromatin clusters and shows CpG island density predicts CBP/p300 dependency.

The paper shows that targeted therapy resistance in cancer selects for cells with higher phenotypic plasticity, which enhances their ability to adapt to other stressors and promotes metastasis.

The paper develops a multiplexed mouse model to study TBX2 subfamily and Egr1 roles in Ras-driven lung cancer, finding Egr1 loss significantly increases tumor size and suggests immune dysregulation.

This study identifies metastasis-initiating osteosarcoma subpopulations that interact with lung and tumor cells to form a metastatic niche, highlighting tumor-stromal interactions as key drivers of metastasis.

This study identifies Erg as a master transcription factor whose upregulation during aging is critical for adult hematopoietic stem cell function and resistance to leukemogenesis.

This study identifies fibrosis as a targetable vulnerability in osteosarcoma lung metastasis by showing nintedanib inhibits metastatic progression through anti-fibrotic effects.

The paper identifies oncogenic reactivation of young L1 transposable elements in colon cancer, showing PLZF loss drives this activity independently of cell division.

The paper identifies case-specific epigenetic alterations in opioid dependence using ChIP-seq and Hi-C, revealing convergent regulatory loci associated with genetic and environmental risk factors.